A carregar...
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
OBJECTIVE: Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations beginning at week 2 in biological-naïve patients with PsA. METHODS: Patients were randomised (1:1) to apremilast 30 mg twice daily or placebo. At week 16, patients whose swollen and tender joint counts ha...
Na minha lista:
| Publicado no: | Ann Rheum Dis |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5909747/ https://ncbi.nlm.nih.gov/pubmed/29343507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2017-211568 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|